Psoriasis is a chronic inflammatory skin disease with genetic background and autoimmune pathogenic traits. 1,2 Biotechnological therapy is a treatment option in moderate-to-severe psoriasis, with favorable benefit-risk balance and no cumulative organ-specific toxicity, which represented one of the most important major research advantages in the management of more severe and unresponsive forms of psoriasis. 3-5 However, biological treatments have been linked to an increased risk of infections. 4 Interleukin (IL)-17 is involved in mucocutaneous defense against extracellular pathogens including Candida

Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis characterized by hyperkeratotic follicular papules and erythematous-desquamative plaques that tend to progressively evolve into erythroderma. Treatment is challenging given that international guidelines are not available and large-scale trials do not exist. Traditionally, many topical and systemic drugs had been used as consolidated agents; recently, biologicals are gaining increasing importance, promisingly dominating the therapeutic scenario ahead. Herein, we present a case series showing the "past" and the "future" therapeutic approaches to erythrodermic PRP, one case treated with acitretin and nb-UVB phototherapy combination, while the other with ustekinumab, performing also a throughout literature review.

Hidradenitis suppurativa (HS) is an inflammatory skin disease showing a chronic-remitting course. It has been rarely reported that long-term inflammation in HS could lead to serious complications like cutaneous squamous cell carcinoma. Cemiplimab is a fully human antibody immunotherapy that inhibits programmed cell death protein-1, approved for the treatment of locally advanced squamous cell carcinoma, or metastatic squamous cell carcinoma, in patients not eligible for curative surgery or radiotherapy. Herein, we report the case of a 56-year-old patient developing an invasive SCC on longstanding and unresponsive HS lesions successfully treated with cemiplimab.

Primary cutaneous peripheral T-cell lymphoma (PTL) not otherwise specified (NOS) is a very rare lymphoma presenting aggressive course and dismal prognosis. 1,2 Herein we report an indolent nasal CD8positive-PTL/NOS in a young female. A 22-year-old female with Down Syndrome presented erythematous-violaceus papules, plaques, and nodules on the middle face, involving the nose, nasolabial sulcus, and cheeks of 5-year duration, progressively worsening (Figure 1A). On examina

We describe a case of frontal fibrosing alopecia (FFA) in a man. Beard trichoscopy can help us make the differential diagnosis with androgenetic alopecia in difficult cases.A healthy 58-year-old man presented to our dermatology service with a 5-year history of diffuse progressive alopecia involving frontotemporal and parietal areas. Clinical evaluation exposed alopecic patches of the beard (Fig 1 ½F1 ). Fig 1. Clinical image of the man who presented with an initial form of frontal fibrosing alopecia with beard involvement.